Acorda MS drug fails goal of post-marketing study
(Reuters) - Acorda Therapeutics Inc said on Monday that a low-dose version of its multiple sclerosis drug Ampyra did not work in a clinical study, a potentially positive result that...
All Stories
Acorda MS drug fails goal of post-marketing study
(Reuters) - Acorda Therapeutics Inc said on Monday that a low-dose version of its multiple sclerosis drug Ampyra did not work in a clinical study, a potentially positive result that...